Table of Contents for Ex. 2008
`
`Document
`
`Page(s)
`
`Provisional Application Cover Sheet (02-08-2007) ......................................... 2
`
`As-filed specification (02-08-2007) .................................................................. 3-38
`
`As-filed claims (02-08-2007) ............................................................................ 39-41
`
`As-filed abstract (02-08-2007) .......................................................................... 42
`
`As-filed drawings (02-08-2007) ....................................................................... 43-44
`
`Electronic Patent Application Fee Transmittal (02-08-2007) .......................... 45-46
`
`Electronic Acknowledgement Receipt (02-08-2007) ....................................... 47-49
`
`Filing Receipt (02-21-2007) ............................................................................. 50-52
`
`Notice to File Missing Parts of Provisional Application (02-21-2007) ............ 53-54
`
`Provisional Application Cover Sheet (04-20-2007) ......................................... 55
`
`Response to Notice to File Missing Parts (04-20-2007) ................................... 56
`
`Electronic Patent Application Fee Transmittal (04-20-2007) .......................... 57-58
`
`Electronic Acknowledgement Receipt (04-20-2007) ....................................... 59-60
`
`Updated Filing Receipt (04-24-2007) ............................................................... 61-63
`
`Updated Filing Receipt (04-25-2007) ............................................................... 64-66
`
`Request for Copy of Application (02-28-2014) ................................................ 67
`
`Electronic Acknowledgement Receipt (02-28-2014) ....................................... 68-69
`
`Page 1 of 69
`
`Biogen Exhibit 2008
`Coalition v. Biogen
`IPR2015-01136
`
`

`
`PROVISIONAL APPLICATION COVER SHEET
`
`This is a request for filing a PROVISIONAL APPLICATION under 3? CFR 1.53(c).
`
`
`
`Docket Number 03201.50-12-ooooo - Type a plus sign {+} inside this box E
`
`
`lNVENTOR(s)IAPPLlCANT(s)
` RESIDENCE (CITY AND EITHER STATE OR FOREIGN
`
`
`COUNTRY)
`
`LAST NAME
`
`FIRST
`NAME
`
`
`
`
`
`
`TITLE OF INVENTION (500 characters max)
`
`Nrf2 SCREENING ASSAYS AND RELATED METHODS AND COMPOSITIONS
`
`CORRESPONDENCE ADDRESS
`
`BIOGEN IDEC I FINNEGAN HENDERSON, LLP
`
`Customer Number 65,779
`
`ENCLOSED APPLICATION PARTS (check all that apply)
`
`D Other: [Number] Pages; [Description]
`
`
`
`METHOD OF PAYMENT
`
`
`IE Specification: 40 Pages E Drawing(s): 2 Sheetsi'2 Figures
`
`
`
`
`
`
`
`
`
`
`The invention was made by an agency of the United States Government or under a contract with an
`agency of the United States Government.
`
`IX No.
`
`I:l Yes, the name of the US. Government agency and the Government contract number are:
`
`[Text]
`
`
`Respectfully submitted on b
`
`SIGNATURE Z 5
`
`Date February 8, 2007
`
`alf of the patent practitioners associated with Customer Number 65,779.
`
`TYPED OR PRINTED NAME Konstantin M. Linnik
`
`REGISTRATION NO. 56,309
`
`|:| Additional inventors are being named on separately numbered sheets attached hereto.
`
`PROVISIONAL APPLICATION FILING ONLY
`
`Page 2 of 69
`
`A check or money order is
`enclosed to cover the Provisional
`
`PROVISIONAL FILING FEE
`
`$200.00
`
`
`
`Application filing fees
`
`
`
`
`
`D
`
`
`
`
`
`Total Number of Pages of specification, drawings,
`If more
`sequence or computer listing, or other papers 42.
`than 100 pages, add $250 for each additional 50 pages or
`fraction thereof.
`
`IE
`The Commissioner is hereby
`authorized to charge any
`
`deficiency or credit any
`
`overpayment in fees to Deposit
` TOTAL FILING FEE
`$200.00
`Account Number 06-0916.
`
`Page 2 of 69
`
`

`
`Attorney Docket No. 08201 .6042-00000
`
`Nrf2 SCREENING ASSAYS
`
`AND RELATED METHODS AND COMPOSITIONS
`
`[0001]
`
`The invention relates to the field of cell and molecular biology and
`
`to the development and use of therapeutic compounds, more particularly,
`
`compounds for treating neurological diseases, including demyelinating
`
`neurological diseases, such as, e.g., multiple sclerosis.
`
`[0002] Multiple sclerosis (MS) is an autoimmune disease with the
`
`autoimmune activity directed against central nervous system (CNS) antigens.
`
`The disease is characterized by inflammation in parts of the CNS, leading to the
`
`loss of the myelin sheathing around neuronal axons (demyelination), loss of
`
`axons, and the eventual death of neurons, oligodenrocytes and glial cells.
`
`[0003]
`
`An estimated 2,500,000 people in the world suffer from MS.
`
`It is
`
`one of the most common diseases of the CNS in young adults. MS is a chronic,
`
`progressing, disabling disease, which generally strikes its victims some time after
`
`adolescence, with diagnosis generally made between 20 and 40 years of age,
`
`although onset may occur earlier. The disease is not directly hereditary,
`
`although genetic susceptibility plays a part in its development.
`
`Relapsing—remitting MS presents in the form of recurrent attacks of focal or
`
`multifocal neurologic dysfunction. Attacks may occur, remit, and recur,
`
`seemingly randomly over many years. Remission is often incomplete and as one
`
`attack follows another, a stepwise downward progression ensues with increasing
`
`permanent neurological deficit.
`
`[0004] Although various immunotherapeutic drugs can provide relief in
`
`patients with MS, none is capable of reversing disease progression, and some
`
`can cause serious adverse effects. Most current therapies for MS are aimed at
`
`the reduction of inflammation and suppression or modulation of the immune
`
`system. As of 2006, the available treatments for MS reduce inflammation and
`
`the number of new episodes but not all have an effect on disease progression. A
`
`number of clinical trials have shown that the suppression of inflammation in
`
`chronic MS rarely significantly limits the accumulation of disability through
`
`Page 3 of 69
`
`Page 3 of 69
`
`

`
`Attorney Docket No. 08201 .6042-00000
`
`sustained disease progression, suggesting that neuronal damage and
`
`inflammation are independent pathologies. Promoting CNS remyelination as a
`
`repair mechanism and otherwise preventing axonal loss and neuronal death are
`
`some of the important goals for the treatment of MS. For a comprehensive
`
`review of MS and its current therapies, see, e.g., McAlpine's Multiple Sclerosis,
`
`by Alastair Compston et al., 4th edition, Churchill Livingstone Elsevier, 2006.
`
`[0005]
`
`“Phase 2 enzymes” serve as a protection mechanism in
`
`mammalian cells against oxygen/nitrogen species (ROS/HNS), electrophiles and
`
`xenobiotics. These enzymes are not normally expressed at their maximal levels
`
`and, their expression can be induced by a variety of natural and synthetic agents.
`
`Nuclear factor E2-related factor 2 (Nrf2) is a transcription factor responsible for
`
`the induction of a variety of important antioxidant and detoxification enzymes that
`
`coordinate a protective cellular response to metabolic and toxic stress.
`
`[0006] ROS/FlNS are most damaging in the brain and neuronal tissue,
`
`where they attack post-mitotic (i.e., non-dividing) cells such as glial cells,
`
`oligodendocytes, and neurons, which are particularly sensitive to free radicals.
`
`This process leads to neuronal damage. Oxidative stress has been implicated in
`
`the pathogenesis of a variety of neurodegenerative diseases, including ALS,
`
`Alzheimer's disease (AD), and Parkinson's disease (PD). For review, see, e.g.,
`
`van Muiswinkel et al., Curr. Drug Targets CNS--Neurol. Disord., 2005, 4:267-281.
`
`An anti-oxidative enzyme under control of Nrf2, NQ01 (NAD(P)H
`
`dehydrogenase, quinone 1), was recently reported to be substantially
`
`upregulated in the brain tissues of AD and PD subjects (Muiswinkel et al.,
`
`Neurobiol. Aging, 2004, 25: 1253). Similarly, increased expression of NQO1 was
`
`reported in the ALS subjects’ spinal cord (Muiswinkel et al., Curr. Drug
`
`Targets--CNS. Neurol. Disord., 2005, 4267-281) and in active and chronic
`
`lesions in the brains of patients suffering from MS (van Horssen et al., Free
`
`Radical Biol. & Med., 2006, 41 311-311). These observations indicate that the
`
`Nrf2 pathway may be activated in neurodegenerative and neuroinflammatory
`
`diseases as an endogenous protective mechanism.
`
`Indeed, most recently, it has
`
`Page 4 of 69
`
`Page 4 of 69
`
`

`
`Attorney Docket No. 08201 .6042-00000
`
`been reported that induced activation of Nrf2—dependent genes by certain
`
`cycIopenanone—based compounds (NEPP) counters the toxic effects of metabolic
`
`inhibition and ROS/RNS production in the brain and protects neurons from death
`
`in vitro and in vivo (see Satoh et al., PNAS, 2006, 103(3):768-773).
`
`[0007] Additionally, many publications have reported neuroprotective
`
`effects of compounds in natural p|ant—derived compounds (“phytochemicals”),
`
`including o—tocophero| (vitamin E), lycopene (tomatoes), resveratrol (red grapes),
`
`sulforaphane (broccoli), EGCG (green tea), etc. For review, see Mattson and
`
`Cheng, Trends in Neurosci., 2006, 29(11):632-639. Originally, the action of
`
`these compounds was attributed to their anti—oxidant properties. However, while
`
`most anti-oxidants are effective only at high concentrations, at least some of
`
`these compounds appear to exert neuroprotective effects at much lower doses.
`
`Emerging evidence suggests that these compounds may exert their
`
`neuroprotective effects by activating cellular stress—response pathways, including
`
`the Nrf2 pathway, resulting in the upregulation of neuroprotective genes.
`
`However, the exact mechanism of action of these compounds remains poorly
`
`understood.
`
`[0008] To date, more than 10 different chemical classes of inducers of
`
`Nrf2 pathway have been identified including isothiocyanates and their thiol
`
`addition products, dithiocarbamates, as well as 1,2—dithio|e—3~thiones, trivalent
`
`arsenic derivatives (e.g., phenyl arsenoxide), heavy metals, certain conjugated
`
`cyclic and acyclic polyenes (including porphyrins, chlorophyllins, and chlorophyll),
`
`and vicinal dimercaptans. These inducers have few structural similarities. They
`
`are mostly electrophiles, and all can react chemically with thiol groups by
`
`alkylation, oxidation, or reduction, suggesting that the intracellular sensor for
`
`inducers is likely to contain very highly reactive (cysteine) thiols. The inducers
`
`can modify thiol groups by a variety of mechanisms including: alkylation (Michael
`
`addition acceptors, isothiocyanates, quinones); oxidation (e.g., peroxides and
`
`hydroperoxides); and direct reaction with thiol/disulfide linkages (e.g., vicinal
`
`dithiols such as 1,2-dimercaptopropanol, lipoic acid). These diverse response
`
`Page 5 of 69
`
`Page 5 of 69
`
`

`
`Attorney Docket No. 08201.6042—00000
`
`mechanisms provide plasticity for cellular responses to a variety of electrophilic
`
`and oxidant stressors.
`
`[0009]
`
`There is a need to develop new treatments, and in particular,
`
`compounds for treating MS that provide neuroprotection. The development of
`
`cell-based and in vitro assays to identify and characterize existing drug
`
`candidates senres this goal.
`
`[0010]
`
`In some embodiments, the invention provides the following
`
`methods:
`
`1) methods of screening for new candidate compounds that may be
`
`useful for treating a neurological disease;
`
`2) methods of evaluating neuroprotective properties of drugs and drug
`
`candidates for treating a neurological disease;
`
`3) methods of comparing (e.g., for bicequivalence) two or more
`
`pharmaceutical compositions which contain fumaric acid derivatives;
`
`4) methods of treating a neurological disease by administering to the
`
`subject in need thereof compounds that are partially structurally
`
`similar to DMF or MMF; and
`
`5) methods of treating a neurological disorder by a combination therapy
`
`that includes administration of a first compound that upregulates the
`
`Nrf2 pathway and a second compound that does not upregulate the
`
`Nrf2 pathway.
`
`[0011] A neurological disease in methods 1-5 above is preferrably a
`
`neurodegenerative disease such as, for example, ALS, Parkinson's disease,
`
`Alzheimer’s disease, and Huntington’s disease. More preferably, the
`
`neurological disease is MS or another demyelinating neurological disease.
`
`[0012] Methods 1-3 of the invention may comprise:
`
`a) contacting a cell with the test compound, and
`
`b) determining whether the Nrf2 pathway is upregulated in the cell.
`
`In some embodiments, the methods may further comprise:
`
`Page 6 of 69
`
`Page 6 of 69
`
`

`
`Attorney Docket No. 08201 .6042—00000
`
`C) determining whether the test compound slows or prevents
`
`demyelination, axonal loss, and/or neuronal death, and/or
`
`d) selecting the test compound as a candidate for treating
`
`neurodegeneration in a neurological disease if 1) the Nrf2 pathway is
`
`upregulated and 2) demyelination, axonal loss, and/or neuronal death
`
`are/is prevented or slowed.
`
`[0013] Methods 1-3 of the invention comprise contacting a cell with test
`
`compound(s) and determining whether the Nrf2 pathway is upregulated in the
`
`cell.
`
`In such methods, an upregulation of the Nrf2 pathway above a threshold
`
`(e.g., by at least 30% over a control) indicates that the compound(s) has/have
`
`certain biological properties beneficial in treating a neurological disease (e.g.,
`
`neuroprotective properties).
`
`In some embodiments, the upregulation of the Nrf2
`
`pathway is assessed (in vivo and/or in vitro) by one or more of the following:
`
`i) expression levels of endogenously produced or exogenously
`
`introduced Nrf2;
`
`ii) subcellular localization and/or nuclear translocation of Nrf2;
`
`iii) expression levels and/or activity of one or more genes under control
`
`of Nrf2 (e.g., endogenous NQO1) or an Nrf2—reguIated reporter gene
`
`in an artificial reporter construct;
`
`iv)
`
`levels of Nrf2 binding to the Nrf2-binding DNA element ARE;
`
`v)
`
`stability of Nrf2/Keap1 complexes; and
`
`vi) modification (e.g., alkylatlon) levels of Keapt and other
`
`Nrf2/Keapi -associated proteins.
`
`[0014]
`
`In some embodiments of methods 1-3, the compounds that are
`
`being screened, evaluated, or compared are mild alkylating agents, and more
`
`specifically, Michael addition acceptors, or compounds that are metabolized upon
`
`administration to Michael addition acceptors.
`
`In some embodiments, such
`
`Michael addition acceptors have the structure of Formula I, II, III, or IV set forth in
`
`the Detailed Description.
`
`Page 7 of 69
`
`Page 7 of 69
`
`

`
`Attorney Docket No. 08201 .6042-00000
`
`[0015]
`
`_In certain embodiments of method 1, the method of screening for
`
`a candidate compound for treating a neurological disease comprises:
`
`a) contacting a cell with a plurality of test compounds,
`
`b) determining whether the Nrf2 pathway is upregulated in the cell, and
`
`C) selecting from the plurality of compounds at least one compound that
`
`upregulates the Nrf2 pathway,
`
`wherein an upregulation of the Nrf2 pathway by the selected compound(s)
`
`indicates that the selected compound(s) may be useful for treating a neurological
`
`disease. The plurality of compounds may be represented, e.g., by a
`
`combinatorial chemical library, and the method may be performed, e.g., by
`
`high-throughput screening.
`
`[0016]
`
`In certain embodiments of method 2, the method of evaluating
`
`neuroprotective properties of a drug or drug candidate for treating a neurological
`
`disease comprises:
`
`a) contacting a cell with the drug or drug candidate, and
`
`b) determining whether the Nrf2 pathway is upregulated in the cell,
`
`wherein an upregulation of the Nrf2 pathway by the drug or drug candidate
`
`indicates that the drug or drug candidate is useful for neuroprotection in treating
`
`a human having a neurological disease.
`
`[0017]
`
`In certain embodiments of method 3, a method of comparing two
`
`or more pharmaceutical compositions (e.g., for bioequivalence) comprises:
`
`a) contacting a cell with a first composition comprising a test compound,
`
`and
`
`b) comparing the level of Nrf2 pathway upregulation in the cell by the
`
`test compound to the corresponding level of the Nn‘2 pathway
`
`upregulation in a control cell treated with a second composition
`
`comprising DMF, MMF, or both.
`
`[0018]
`
`In some embodiments of method 3, the test compound is fumaric
`
`acid, a salt thereof, or a fumaric acid derivative.
`
`In some embodiments, the first
`
`composition comprises DMF, MMF, or both.
`
`In some embodiments, the dose
`
`Page 8 of 69
`
`Page 8 of 69
`
`

`
`Attorney Docket No. 08201 .6042—00000
`
`and/or the formulation of the first composition differs from the dose and/or the
`
`formulation of the second composition.
`
`[0019]
`
`In some embodiments. method 3 further comprises:
`
`c) comparing at least one pharmacokinetic parameter (e.g.,
`
`serum—half—life) of the first and the second compositions.
`
`[0020]
`
`In some embodiments of method 4, the method of treating a
`
`mammal having a neurological disease comprises administering to the mammal
`
`a therapeutically effective amount of a neuroprotective compound having
`
`Formula I, II, III, or IV, e.g., a fumaric acid derivative (e.g., DMF or MMF).
`
`[0021]
`
`In some embodiments of method 4, the invention provides a
`
`method of slowing or preventing neurodegeneration (more specifically, e.g.,
`
`demyelination, axonal loss, and/or neuronal death) in a patient in need thereof,
`
`by administering the compound in an amount and for a period of time sufficient to
`
`slow or prevent demyelination, axonal loss, and/or neuronal death, e.g., by at
`
`least 30% relative to a control.
`
`[0022]
`
`In certain embodiments of method 5, the method of treating a
`
`mammal having a neurological disease by combination therapy comprises:
`
`a) administering to the mammal a therapeutically effective amount of a
`
`first compound that upregulates the Nrf2 pathway, and
`
`b) administering a therapeutically effective amount of a second
`
`compound that does not upregulate the Nrf2 pathway.
`
`[0023]
`
`In some of embodiments of method 5, the first compound, used in
`
`step (a), is a compound of Formula I, II, III, or IV, e.g., a fumaric acid derivative
`
`(e.g., DMF or MMF); and the second compound, which is used in step (b), is an
`
`immunosuppressive or an immunomodulatory compound that does not
`
`upregulate the Nrf2 pathway (e.g., by more than 30% over a control).
`
`[0024]
`
`In some embodiments of method 5, the method of treating a
`
`neurological disease in a mammal comprises administering to the mammal a
`
`therapeutically effective amount of a compound of Formula I, II, III, or IV.
`
`Page 9 of 69
`
`Page 9 of 69
`
`

`
`Attorney Docket No. 08201 15042-00000
`
`[0025]
`
`In some of the embodiments of methods 1-5, the compound being
`
`screened, identified, evaluated, or used for treating a neurological disorder is not
`
`fumaric acid or its salt, or a fumaric acid derivative (e.g., DMF or MMF).
`
`[0026] Other features and embodiments of the invention will be apparent
`
`from the following description and the claims.
`
`BRIEF DESCRIPTION OF THE FIGURES
`
`[0027] Figure 1 demonstrates that DMF and MMF are potent activators
`
`of Nrf2 at concentrations within clinical exposure range (cells in culture).
`
`[0028] Figure 2 shows results of FtNAi experiments.
`
`DETAILED DESCRIPTION
`
`[0029] The present invention is based, in part, on the discovery that
`
`dimethyl fumarate (DMF) and monomethyl fumarate (MMF) are potent activators
`
`of the Nrf2 pathway, a major neuroprotective and anti-inflammatory mechanism.
`
`The invention is further based, at least in part, on the finding that DMF and MMF
`
`are neuroprotective (myelinoprotective and axonoprotective) in a mouse model of
`
`autoimmune neurodegenerative disease.
`
`[0030] Due to the involvement of Nrf2 in the regulation of cellular
`
`response to metabolic stress, survival and inflammation, DMF, MMF, and other
`
`Nrf2 activators may be useful for therapeutic management of a variety of
`
`inflammatory, ischemic, and neurodegenerative processes.
`
`[0031] Fumaric acid esters, such as DMF, have been proposed for
`
`treatment of MS (see, e.g., Schimrigk et al., Eur. J. Neurol., 2006, ‘l3(6):604-10;
`
`Drugs Fl&D, 2005, 6(4):229—30).
`
`[0032] DMF activates a major cytoprotective (neuroprotective) and
`
`anti—inflammatory mechanism not targeted by current therapies. Thus, the
`
`findings that DMF activates the Nrf2 pathway and has a neuroprotective effect,
`
`offer a rationale for the use of DMF in combination with immunosuppressive or
`
`Page 10 of 69
`
`Page 10 of 69
`
`

`
`Attorney Docket No. 08201 .6042-00000
`
`immunodulatory therapeutics that do not upregulate the Nrf2 pathway. The
`
`invention further provides means for identifying compounds with a new
`
`therapeutic modality useful in multiple neurological indications and
`
`complementary to other drugs for the treatment of a neurological disease,
`
`including a number of currently used immunomodulators.
`
`[0033] DMF is a member of a large group of antioxidant molecules
`
`known for their cytoprotective and anti-inflammatory properties. These
`
`molecules also share the property of the Nrf2 pathway activation. Thus, the
`
`finding that DMF activates the Nrf2 pathway in conjunction with the
`
`neuroprotective effects of DMF further offers a rationale for identification of
`
`structurally and/or mechanistically related molecules that would be expected to
`
`be therapeutically effective for the treatment of neurological disorders, such as,
`
`e.g., MS.
`
`I. Definitions
`
`[0034] Certain terms are defined in this section; additional definitions are
`
`provided throughout the description.
`
`[0035] The terms “activation" and “upregulation,” when used in reference
`
`to the Nrf2 pathway, are used interchangeably herein.
`
`[0036] The terms “disease” and “disorder” are used interchangeably
`
`herein.
`
`'
`
`[0037] The term “a drug for treating a neurological disease“ refers to a
`
`compound that has a therapeutic benefit in a specified neurological disease as
`
`shown in at least one animal model of a neurological disease or in human clinical
`
`trials for the treatment of a neurological disease.
`
`[0038] The term “neuroprotection” and its cognates refer to prevention or
`
`a slowing in neuronal degeneration, including, for example, demyelination and/or
`
`axonal loss, and optionally, neuronal and oligodendrocyte death. Neuroprotection
`
`may occur through several mechanisms, e.g., through reducing inflammation,
`
`providing neurotrophic factors, scavenging free radicals, etc. As used herein, a
`
`compound is considered neuroprotective if it (1) upregulates the Nrf2 pathway
`
`Page 11 of 69
`
`Page 11 of 69
`
`

`
`Attorney Docket No. 08201 .6042-00000
`
`above a certain threshold and (2) provides neuroprotection, regardless of
`
`possible other mechanisms of action.
`
`[0039] The terms “treatment," “therapeutic method," “therapeutic
`
`benefits,” and the like refer to therapeutic as well as prophylactic/preventative
`
`measures. Thus, those in need of treatment may include individuals already
`
`having a specified disease and those who are at risk for acquiring that disease.
`
`[0040] The terms “therapeutically effective dose” and “therapeutically
`
`effective amount” refer to that amount of a compound which results in prevention
`
`or delay of onset or amelioration of symptoms of a neurological disorder in a
`
`subject or an attainment of a desired biological outcome, such as reduced
`
`neurodegeneration (e.g., demyelination, axonal loss, and neuronal death) or
`
`reduced inflammation of the cells of the CNS.
`
`II.
`
`Methods of Evaluating Compounds
`
`[0041]
`
`In one aspect, the invention provides method of evaluating
`
`neuroprotective properties of test compounds, including the following methods:
`
`1) methods of screening for new candidate compounds that may be
`
`useful for treating a neurological disease;
`
`2) methods of evaluating neuroprotective properties of drugs and
`
`candidates that are used or proposed for treating a neurological
`
`disease;
`
`3) methods of comparing (e.g., for bioequivalence) two or more
`
`pharmaceutical compositions which contain fumaric acid
`
`derivatives;
`
`[0042] Methods 1-3 of the invention may comprise:
`
`'
`
`a) contacting a cell with the test compound,
`
`b) determining whether the Nrf2 pathway is upregulated in the cell,
`
`and, in some embodiments, additionally performing the following step(s):
`
`c) determining whether the test compound slows or prevents
`
`demyelination, axonal loss, and/or neuronal death, and/or
`
`Page 12 of 69
`
`10
`
`Page 12 of 69
`
`

`
`Attorney Docket No. 08201 .6042-00000
`
`d) selecting the test compound as a candidate for treating
`
`neurodegeneration in a neurological disease it 1) the Nrl2 pathway is
`
`upregulated and 2) demyelination, axonal loss, and/or neuronal death
`
`are/is prevented or slowed.
`
`[0043] Methods 1-3 are described in detail below.
`
`Method 1: Methods of screening
`
`[0044] The invention provides methods of screening for a candidate
`
`compound for treating a neurological disease. Such methods comprise:
`
`a) contacting a cell with a plurality of test compounds,
`
`b) determining whether the Nrf2 pathway is upregulated in the cell, and
`
`c) selecting from the plurality of compounds at least one compound that
`
`upregulates the Nrf2 pathway,
`
`wherein an upregulation of the Nrf2 pathway by the selected compound(s)
`
`indicates that the selected compound(s) may be useful for treating a neurological
`
`disease. For example, the plurality of compounds may be represented by a
`
`combinatorial chemical library, and the screening method may be performed by a
`
`high-throughput screening as described in, e.g., High-Throughput Screening in
`
`Drug Discovery (Methods and Principles in Medicinal Chemistry), by Jorg Htlser
`
`(ed.), John Wiley & Sons (2006).
`
`[0045] Combinatorial libraries of compounds are also described in, e.g.,
`
`Solid-Supported Combinatorial and Parallel Synthesis of Small-Molecular-Weight
`
`Compound Libraries (Tetrahedron Organic Chemistry) Ian Salusbury (ed.),
`
`Elsevier (1998); Combinatorial Libraries: Synthesis, Screening and Application
`
`Potential (Library Binding), by Riccardo Cortese (ed.), Walter de Gruyter (1995).
`
`The libraries of compounds may be, for example, quinone libraries and other
`
`libraries as described in Mittoo, Comb. Chem. & High Throughput Screen, 2006,
`
`9:421 -423.
`
`[0046]
`
`In some embodiments, the compounds that are being screened
`
`and/or selected comprise at least one or a plurality of mild alkylating agents, and
`
`11
`
`Page 13 of 69
`
`Page 13 of 69
`
`

`
`Attorney Docket No. 08201 .6042-00000
`
`more particularly, Michael addition acceptors or compounds that are metabolized
`
`to Michael addition acceptors, including compounds of Formulas I, II, III, or IV.
`
`[0047]
`
`In some of the embodiments, the compounds comprise fumaric
`
`acid, its salt(s), and/or fumaric acid derivative(s).
`
`Methods 2: Methods of evaluating drugs and drug candidates
`
`[0048] The invention further provides methods of evaluating
`
`neuroprotective properties of a drug or drug candidate for treating a neurological
`
`disease. Such methods comprise:
`
`a) contacting a cell with the drug or drug candidate, and
`
`b) determining whether the Nrf2 pathway is upregulated in the cell,
`
`wherein the upregulation of the Nrl2 pathway by the drug or drug candidate
`
`indicates that the drug or drug candidate is neuroprotective in treating a human
`
`having a neurological disease.
`
`[0049]
`
`in some embodiments, the upregulation of the Nrf2 pathway by
`
`the drug or drug candidate indicates that the drug or drug candidate has the
`
`ability to slow demyelination, the loss of axons, and/or neuronal death.
`
`[0050]
`
`In some embodiments, the method of evaluating a drug or drug
`
`candidate comprise an additional step:
`
`c) evaluating demyelination, loss of axons, and/or neuronal death.
`
`[0051]
`
`In some embodiments, steps a) and c) are performed in vivo in at
`
`least one model of a neurological disease, e.g., as described below.
`
`[0052]
`
`In other embodiments, particularly those in which the neurological
`
`disease is multiple sclerosis or another demyelinating disease, the evaluated
`
`drug or drug candidate for a neurological disease is chosen from the following:
`
`FTY720 (2—(4—octylphenethy|)—2~aminopropane—1,3-diol; Novartis); anti—lL12
`
`antibody (e.g., ABT-874; Abbott Laboratories); GSK683699 (GSK/Tanabe);
`
`Neurovax (Immune Response Corp.; Darlington, Curr. Opin. Moi. Ther., 2005,
`
`7(6):598-603); anti-CCR2 antibody (e.g., MLN 1202; Millennium); interferon [3-1a
`
`(e.g., Avonex®; Biogen Idec); anti-a4-integrin antibody (e.g., Tysabri®; Biogen
`
`ldec/Elan); anti-CD20 antibody (e.g., Flituxan® (Biogen ldec/Genentech);
`
`Page 14 of 69
`
`12
`
`Page 14 of 69
`
`

`
`Attorney Docket No. 08201 15042-00000
`
`TV 5010 (Teva); NBI-788 (Neurocrine); MBP8298 (BioMS (see Warren et al.,
`
`Eur. J. Neurol., 2006, 13(8):887-95); Mylinax (Oral Cladribine;
`
`2—chIorodeoxyadenosine; Serono/IVAX); Teriflunomide
`
`((Z)—2—cyano—N—(4—(trif|uoromethyI)phenyI)—3-hydroxybut~2-enamide;
`
`Sanofi-Aventis); Temsirolimus (Wyeth); Laquinimod
`
`(5-chloro-N-ethyi-1,2-dihydro~4-hydroxy-1-methyI-2-oxo-N-phenylquinoline-3—car
`
`boxamide; Active Biotech/Teva); and interferon tau (Tauferon; Pepgen).
`
`[0053]
`
`In some embodiments, the drug or drug candidate being
`
`evaluated is a mild alkylating agent, and more specifically, a Michael addition
`
`acceptor, or a compound that is metabolized to a Michael addition acceptor,
`
`including compounds of Formulas I, II, III, or IV.
`
`[0054]
`
`In some of the embodiments, the compound is fumaric acid, its
`
`salt, or a fumaric acid derivative.
`
`Method 3: Methods of methods of evaluating neurogrotective properties
`
`[0055] The invention further provides methods of comparing (e.g., for
`
`bioequivalence) two or more pharmaceutical compositions. Such methods
`
`comprise:
`
`a) contacting a cell with a first composition comprising a test compound,
`
`and
`
`b) comparing the level of the Nn‘2 pathway upregulation in the cell by
`
`the test compound to the corresponding level of the Nri2 pathway
`
`upregulation in a cell treated with a second composition (“comparator
`
`composition”) comprising DMF, MMF, or both.
`
`[0056]
`
`In some embodiments, substantially dissimilar levels of
`
`upregulation by the first and second compositions indicate that the compositions
`
`are not bioequivalent.
`
`[0057]
`
`In some embodiments, the test compound is fumaric acid, its salt
`
`thereof, a fumaric acid derivative, or mixtures thereof.
`
`In some embodiments, the
`
`first composition comprises DMF, MMF, or both.
`
`In some embodiments, the
`
`dose and/or the formulation of the first composition differs from the dose and/or
`
`Page 15 of 69
`
`13
`
`Page 15 of 69
`
`

`
`Attorney Docket No. 082013042-00000
`
`the formulation of the second composition. The first composition may be a
`
`controlled release composition such as, e.g., compositions described in
`
`W0 2006/037342.
`
`[0058]
`
`In some embodiments, the method further comprises and
`
`additional step:
`
`c) comparing at least one pharmacokinetic parameter of the first and
`
`the second compositions.
`
`[0059] Pharmacokinetic parameters and methods for evaluating the
`
`same are well known and are described in, e.g., Pharmacokinetics, Second
`
`Edition (Drugs and the Pharmaceutical Sciences) by Milo Gibaldi et al. (eds.),
`
`lnforma Healthcare (1982). Examples of such pharmacokinetic parameters that
`
`can be evaluated include serum half-life, clearance, and volume distribution.
`
`[0060]
`
`In some embodiments, substantially dissimilar pharmacokinetic
`
`parameter(s) of the first and second compositions indicate that the compositions
`
`are not bioequivalent.
`
`[0061]
`
`In some embodiments, the test compound being evaluated is a
`
`mild alkylating agent, and more specifically, a Michael addition acceptor, or a
`
`compound that is metabolized to a Michael addition acceptor.
`
`[0062]
`
`In some of the embodiments, the test compound is fumaric acid or
`
`its salt, or a fumaric acid derivative.
`
`Ill. Methods of Treatment
`
`[0063] The invention provides methods of treating a mammal who has or
`
`is at risk for developing a neurological disease, including the following methods:
`
`4) methods of treating a neurological disease by administering to the
`
`subject in need thereof compounds that are partially structurally
`
`similar to DMF or MMF (including compounds selected using
`
`methods 1-3 described above) ; and
`
`5) methods of treating a neurological disorder by a combination
`
`therapy that includes administration of a first compound that does
`
`14
`
`Page 16 of 69
`
`Page 16 of 69
`
`

`
`Attorney Docket No. 08201 .6042-00000
`
`not upregulate the Nrf2 pathway and a second compound that
`
`upregulates the Nrf2 pathway.
`
`[0064] Methods 4-5 are described in detail below.
`
`Method 4: Treatment methods
`
`[0065] The invention further provides methods of treating a neurological
`
`disease by administering to the subject in need thereof compounds that are
`
`partially structurally similar to DMF or MMF.
`
`[0066]
`
`In some embodiments of method 4, the invention provides a
`
`method of treating a mammal who has or is at risk for a neurological disease.
`
`The method comprises administering to a mammal a therapeutically effective
`
`amount of a neuroprotective compound which has Formula I, II, III